House panel clears FDA bills giving more post-market authority

06/19/2007 | Reuters · Wall Street Journal, The

A House subcommittee approved a package of bills to overhaul drug-safety laws and give the FDA additional powers to require studies, limit distribution or order label changes for drugs on the market. The panel also replaced language that would have allowed the health secretary to ban new drug ads on television with a provision allowing the FDA to fine companies $250,000 for showing false or misleading ads directed at consumers.

View Full Article in:

Reuters · Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD